180 related articles for article (PubMed ID: 25588772)
41. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer.
Martin JM; Handorf EA; Price RA; Cherian G; Buyyounouski MK; Chen DY; Kutikov A; Johnson ME; Ma CM; Horwitz EM
Med Dosim; 2015; 40(3):186-9. PubMed ID: 25595491
[TBL] [Abstract][Full Text] [Related]
42. Imaging biomarkers in prostate cancer: role of PET/CT and MRI.
Picchio M; Mapelli P; Panebianco V; Castellucci P; Incerti E; Briganti A; Gandaglia G; Kirienko M; Barchetti F; Nanni C; Montorsi F; Gianolli L; Fanti S
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):644-55. PubMed ID: 25595344
[TBL] [Abstract][Full Text] [Related]
43. Curcumin-based anti-prostate cancer agents.
Chen QH
Anticancer Agents Med Chem; 2015; 15(2):138-56. PubMed ID: 25594891
[TBL] [Abstract][Full Text] [Related]
44. Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer.
Polders DL; Steggerda M; van Herk M; Nichol K; Witteveen T; Moonen L; Nijkamp J; van der Heide UA
Acta Oncol; 2015 Jun; 54(6):839-46. PubMed ID: 25591817
[TBL] [Abstract][Full Text] [Related]
45. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.
Murray LJ; Thompson CM; Lilley J; Cosgrove V; Franks K; Sebag-Montefiore D; Henry AM
Phys Med Biol; 2015 Feb; 60(3):1237-57. PubMed ID: 25590229
[TBL] [Abstract][Full Text] [Related]
46. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer.
Dolezel M; Odrazka K; Zouhar M; Vaculikova M; Sefrova J; Jansa J; Paluska P; Kohlova T; Vanasek J; Kovarik J
Strahlenther Onkol; 2015 Apr; 191(4):338-46. PubMed ID: 25589224
[TBL] [Abstract][Full Text] [Related]
47. Prospective evaluation of early postoperative male and female sexual function after radical prostatectomy with erectile nerves preservation.
Tran SN; Wirth GJ; Mayor G; Rollini C; Bianchi-Demicheli F; Iselin CE
Int J Impot Res; 2015; 27(2):69-74. PubMed ID: 25588959
[TBL] [Abstract][Full Text] [Related]
48. Unusual lymph node metastases of prostate cancer detected by 18F-fluorocholine PET/CT.
Pinaquy JB; Allard JB; Cornelis F; Pasticier G; De Clermont H
Clin Nucl Med; 2015 Apr; 40(4):e255-7. PubMed ID: 25674860
[TBL] [Abstract][Full Text] [Related]
49. Natural history of surgically treated high-risk prostate cancer.
Briganti A; Karnes RJ; Gandaglia G; Spahn M; Gontero P; Tosco L; Kneitz B; Chun FK; Zaffuto E; Sun M; Graefen M; Marchioro G; Frohneberg D; Giona S; Karakiewicz PI; Van Poppel H; Montorsi F; Joniau S;
Urol Oncol; 2015 Apr; 33(4):163.e7-13. PubMed ID: 25665508
[TBL] [Abstract][Full Text] [Related]
50. Impact of obesity upon prostate cancer-associated mortality: A meta-analysis of 17 cohort studies.
Zhang X; Zhou G; Sun B; Zhao G; Liu D; Sun J; Liu C; Guo H
Oncol Lett; 2015 Mar; 9(3):1307-1312. PubMed ID: 25663903
[TBL] [Abstract][Full Text] [Related]
51. Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.
Jain S; Loblaw A; Vesprini D; Zhang L; Kattan MW; Mamedov A; Jethava V; Sethukavalan P; Yu C; Klotz L
J Urol; 2015 Jul; 194(1):79-84. PubMed ID: 25660208
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?
Weller MA; Kupelian PA; Reddy CA; Stephans KL; Tendulkar RD
Clin Genitourin Cancer; 2015 Jun; 13(3):e183-9. PubMed ID: 25660127
[TBL] [Abstract][Full Text] [Related]
53. High risk of under-grading and -staging in prostate cancer patients eligible for active surveillance.
Heidegger I; Skradski V; Steiner E; Klocker H; Pichler R; Pircher A; Horninger W; Bektic J
PLoS One; 2015; 10(2):e0115537. PubMed ID: 25658878
[TBL] [Abstract][Full Text] [Related]
54. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
[TBL] [Abstract][Full Text] [Related]
55. Who bears the greatest burden of aggressive treatment of indolent prostate cancer?
Mahal BA; Cooperberg MR; Aizer AA; Ziehr DR; Hyatt AS; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Orio PF; Trinh QD; Nguyen PL
Am J Med; 2015 Jun; 128(6):609-16. PubMed ID: 25644324
[TBL] [Abstract][Full Text] [Related]
56. Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.
Hegarty SE; Hyslop T; Dicker AP; Showalter TN
PLoS One; 2015; 10(2):e0118430. PubMed ID: 25706657
[TBL] [Abstract][Full Text] [Related]
57. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?
Bokhorst LP; Venderbos LD; Schröder FH; Bangma CH; Steyerberg EW; Roobol MJ
J Urol; 2015 Aug; 194(2):336-42. PubMed ID: 25698407
[TBL] [Abstract][Full Text] [Related]
58. Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening.
Gelfond J; Choate K; Ankerst DP; Hernandez J; Leach RJ; Thompson IM
J Urol; 2015 Jul; 194(1):46-51. PubMed ID: 25686543
[TBL] [Abstract][Full Text] [Related]
59. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.
Dinh KT; Mahal BA; Ziehr DR; Muralidhar V; Chen YW; Viswanathan VB; Nezolosky MD; Beard CJ; Choueiri TK; Martin NE; Orio PF; Sweeney CJ; Trinh QD; Nguyen PL
J Urol; 2015 Aug; 194(2):343-9. PubMed ID: 25681290
[TBL] [Abstract][Full Text] [Related]
60. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
